Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (DP1CA216873)
Article History
Received: 4 October 2018
Accepted: 22 August 2019
First Online: 18 September 2019
Competing interests
: B.E.B. declares outside interests in Fulcrum Therapeutics, 1CellBio, Nohla Therapeutics, HiFiBio, Arsenal BioSciences, Biomillenia and Cell Signaling Technologies. B.E.B., W.A.F, and D.R.T. are named inventors on a patent application related to the detection and modification of insulators.